SAN DIEGO--(BUSINESS WIRE)--The economic uncertainty rocking biopharma, the historic Nortel auction, dealmaking in China, new valuation strategies, lightening-speed convergence of technologies and other pivotal issues will bring over 1,000 of the world’s leading intellectual property (IP), licensing and business development leaders to the Licensing Executives Society (U.S.A. & Canada), Inc., Annual Meeting, October 16-19 at the Manchester Grand Hyatt in San Diego.
“This will be the premier licensing meeting of the year,” said LES (USA & Canada) President Michael Lasinski. “The program is interactive, diverse and relevant to all sectors of the IP, licensing, business development and legal communities. We have assembled a stellar lineup of executive presenters from Boeing, Pfizer, Apple, Merck, Microsoft, Roche and other major corporations who will offer industry-specific insights, proven tools, timely information and deal connections that simply can’t be matched by any other event.”
The program will allow attendees to tailor their experience to suit their professional needs. Expected to attend are professionals and thought leaders from top companies, research institutions, government labs and other technology-oriented organizations, who will select from an array of networking events, interactive plenary and mini-plenary discussions and small group workshops that promote industry-specific education, as well as cross-sector discussions. For a list of featured industry-leading speakers and registrants, visit www.LES2011.org.
“LES has assembled a cadre of leading experts to discuss and provide vital insights into innovative deal-making, risk sharing and other strategies that have proven successful for their companies. These experiences will offer us practical take-home guidance as we all work to creatively navigate through these challenging times,” said Pamela Demain, LES Plenary Program Chair and Executive Director, Corporate Licensing, Merck.
Meeting Highlights
“Can Biopharma Still Create Value…And How?” Tough economic times have put big pharma and biotechs on the critical list. With shrinking budgets, drug pipelines, R&D and venture money can it be revived? Ed Saltzman, President of Defined Health, and Roger Longman, Chief Executive Officer of Real Endpoints LLC (formerly Managing Director, Windhover Information) debate some radical solutions during a featured plenary session.
The
Insiders' Perspective on the Nortel Auction: What Really Happened and
What It Means
An exclusive briefing
featuring key Nortel auction architects, who will offer a first-time,
behind-the-scenes look at what it took to make this historic deal come
together. Speakers include: Kasim Alfalahi, Ericsson, Chief IP Officer
and VP; David Berten, GIPLG, Debtor IP Advisor; David Descoteaux,
Lazard, Debtor Investment Banker; David Kaefer, Microsoft, General
Manager, IP Licensing; Mike Lasinski, 284 Partners, LLC, Creditor IP
Advisor and President of LES (USA & Canada) and John Veschi, Nortel
former Chief IP Officer, Debtor IP Leader.
“The Challenges and Rewards of Doing Business in China – IP Rights, Technology Transfer and Collaboration as Business Tools” Top executives from DuPont, Microsoft, GM, and P&G will provide insight on how IP rights are being leveraged to successfully conduct business in China.
“Dealmaking Challenges in Today’s Turbulent Environment” Top executives from Apple, Celgene, Qualcomm and Pfizer will address challenges in innovation, commercialization, partnering and transactional execution and suggest the best tools and strategies for tackling these challenges.
“Deals Done – Reflecting on the Life of the Deal” Top executives from Roche, Boeing, Gilead, and Samsung will reflect on past deals -- what worked, what didn’t. Attendees will hear what these executives would do differently and how they are adjusting transactions on the fly to manage the realities of today’s changing environment.
Highly Anticipated Announcements
Groundbreaking High Tech Royalty Rate and Deal Terms Survey Results – The LES High Technology Sector will release preliminary findings from its inaugural Royalty Rates and Deals Terms Survey. The new data will provide exclusive and valuable benchmarks for dealmaking in the industry.
LES Deals of Distinction Award -- LES will present its annual Deals of Distinction™ Awards to the best licensing deals of the year in five industry sectors.
For more info and to register for the meeting, go to www.les2011.org.